ISPOR Europe 2024
Meet Fortrea’s Market Access Consulting & HEOR team at ISPOR Europe 2024
Meet us in Barcelona, Spain from November 17-20 as we take part in the leading European conference for health economics and outcomes research (HEOR). While at ISPOR Europe 2024, we invite you to meet with our team of Market Access Consulting & HEOR professionals who will be on hand to discuss the key challenges you are facing in market access, pricing and health economics. With Fortrea's market access and HEOR expertise, we identify evidence gaps and design and execute custom projects to support your product and stakeholder needs. Rely on us to help ensure you are equipped to demonstrate the full value of your product across the audiences of regulators, providers, payers, policymakers and patients.
Stop by any one of the six posters Fortrea is presenting and connect with our subject matter experts presenting them, as well as Gordon Cummins, Senior Director, Global Growth Lead, Fortrea Market Access Consulting & HEOR, who will be attending.
Présentations
18 November 2024 | 16:00 - 19:00 | Poster Session 2
Use of External Control Arms in Reimbursement Submissions: A Review of CAR-T Appraisals by NICE and CDA
Comentale S12, Messina P1, Daniel S3, Jin G2, Szende A2
1Fortrea, Milan, Italy, 2Fortrea, Maidenhead, UK, 3Fortrea, Tel Aviv, Israel
18 November 2024 | 16:00 - 19:00 | Poster Session 2
Emerging Trends in the Adoption of Alternative Financing Models for Advanced Therapy Medicinal Products: A Scoping Review
Cardoso A1, Wallace M2
1Fortrea, Lisbon, Portugal, 1Fortrea, Maidenhead, UK
19 November 2024 | 10:30 - 13:30 | Poster Session 3
Socioeconomic Indicators of Self-Reported Health Based on EQ-5D-5L: Results From General Population Surveys in England and Spain
Szende A1, Feng YS2, Janssen MF3
1Fortrea, York, North Yorkshire, UK, 2Medical University of Tübingen, Tübingen, Baden-Württemberg, Germany, 3The EuroQol Group, Rotterdam, Rotterdam, Netherlands
19 November 2024 | 10:30 - 13:30 | Poster Session 3
Setting Diversity Enrollment Goals in Clinical Trials Based on Real-World Data: Potential Challenges With Multi-Country Requirements
Plante K1, Kiri V2, Knight T3, Howell A4
1Fortrea Inc., Gaithersburg, MD, USA, 2Fortrea Inc., Guildford, SRY, UK, 3Fortrea Inc., Princeton, NJ, USA, 4Fortrea Inc., London, London, UK
19 November 2024 | 16:00 - 19:00 | Poster Session 4
Use of Secondary Real-World Data From the United States to Fulfill European Medicines Agency Post Authorization Requirement
Knight T1, Plante K2, Ruggieri A3
1Fortrea Inc., Greenwood, IN, USA, 2Fortrea Inc., Guildford, SRY, UK, 3Angelini Pharma S.p.A, Rome, Italy
19 November 2024 | 16:00 - 19:00 | Poster Session 4
A Framework for Assessing the Viability of an Externally Controlled Arm for a Single-Arm Trial
Kiri V1, Anastassopoulos KP2
1Fortrea Inc., Guildford, SRY, UK, 2Fortrea, Inc., Gaithersburg, MD, USA